S. Hussein

Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial

Guizhen Wu, Jin Zhang, W. Lei, 2022, Signal Transduction and Targeted Therapy.

Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates

H. Khalak, A. Oulhaj, R. Halwani, 2022, Nature Communications.

Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial

Guizhen Wu, Jin Zhang, W. Lei, 2022, Nature Communications.

Assessing and addressing barriers towards MDI use in acute asthma exacerbations at a tertiary pediatric ED in the United Arab Emirates

Sofia Konstantinopoulou, M. Borg, S. Hussein, 2021, International journal of pediatrics & adolescent medicine.

Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial

Guizhen Wu, Zhixin Ma, Shi Chen, 2023, Signal Transduction and Targeted Therapy.

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.

M. Hassany, A. Pan, Xiaoming Yang, 2021, JAMA.

Safety and Immunogenicity of the NVX-CoV2373 Vaccine as a Booster in Adults Previously Vaccinated with the BBIBP-CorV Vaccine: An Interim Analysis

S. Toback, M. Rousculp, R. Mallory, 2023, medRxiv.

The incidence of COVID-19 infection following emergency use authorization of BBIBP-CORV inactivated vaccine in frontline workers in the United Arab Emirates

A. Oulhaj, M. Sheek-Hussein, Yunkai Yang, 2022, Scientific reports.

Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variants

Z. Liu, Xin Zhang, K. Xu, 2022, medRxiv.